Tissue transglutaminase (TG2) is a calcium-dependent enzyme found in human cells that catalyzes the formation of covalent bonds between glutamine and lysine residues in proteins. It functions in protein stabilization, wound healing, and apoptosis. Abnormal immune reactions to TG2 are central to celiac disease pathology.
When activated by calcium ions, TG2 transfers an acyl group from a glutamine residue in one protein to a lysine residue in another, creating an amide bond. This process, known as transamidation, results in protein cross-linking. The reaction is irreversible and alters protein structure and function. TG2 is expressed in many tissues, especially the small intestine, skin, and liver.
Unlike other transglutaminases, TG2 is not secreted. It resides primarily in the cytoplasm and extracellular matrix. Its activity is tightly regulated by calcium concentration and redox state. Under normal conditions, TG2 contributes to tissue repair and extracellular matrix remodeling. When dysregulated, it becomes a target for autoimmune responses.
TG2 operates through a two-step mechanism. First, it forms a thioester intermediate with the γ-carboxamide group of a glutamine side chain. Second, this intermediate attacks the ε-amino group of a lysine residue in another protein molecule. The result is a stable isopeptide bond between the two proteins.
This cross-linking stabilizes protein aggregates and prevents degradation. In wound healing, TG2 strengthens the extracellular matrix by linking fibronectin and collagen. In apoptosis, it helps package cellular debris for removal by phagocytes. These roles explain why TG2 is abundant in healing tissues and during inflammation.
A single TG2 molecule can modify multiple substrates. It acts on both intracellular and extracellular proteins. For example, it cross-links fibrinogen during blood clotting and modifies α-smooth muscle actin in fibrotic tissues. Its broad substrate specificity allows it to influence diverse biological processes, including fibrosis, neurodegeneration, and cancer progression.
TG2 exists in several functional states depending on calcium levels and redox environment:
| State | Calcium Level | Redox State | Function |
|---|---|---|---|
| Latent | Low | Reduced | Inactive; folded conformation |
| Active | High | Reduced | Cross-links proteins; involved in repair |
| Oxidized | High | Oxidized | Enzymatically inactive; may serve structural role |
The enzyme's activity is also modulated by binding partners. It interacts with integrins, fibronectin, and heat shock proteins. These interactions localize TG2 to specific subcellular compartments and regulate its access to substrates.
Genetic variants of the TGM2 gene exist, but none are strongly linked to disease in large population studies. However, elevated TG2 expression correlates with poor prognosis in certain cancers, such as breast and ovarian carcinoma.
TG2 is essential in maintaining tissue integrity. In the small intestine, it cross-links proteins in the basement membrane, supporting epithelial barrier function. After injury, increased TG2 activity promotes fibroblast migration and matrix deposition during wound closure.
Its role in celiac disease is well-documented. When gliadin peptides from gluten enter the intestinal mucosa, they trigger deamidation of specific glutamine residues by TG2. This modification increases their immunogenicity. The immune system then generates antibodies against both gliadin and TG2, leading to chronic inflammation and villous atrophy.
Testing for anti-TG2 antibodies is a standard diagnostic tool for celiac disease. A positive result indicates ongoing immune activation. Levels correlate with disease severity and response to gluten-free diet. A study published in Gastroenterology found that 95% of patients with biopsy-proven celiac disease had detectable IgA anti-TG2 antibodies (Ludvigsson et al., 2014).
Non-celiac gluten sensitivity may also involve TG2. Some individuals report symptom improvement on a gluten-free diet despite negative serology. Research suggests that TG2 may still be activated by gluten fragments in these cases, though the mechanism remains unclear.
TG2 is often mistaken for tissue transglutaminase type 1 (TG1), which is expressed in the skin and involved in cornification. TG1 deficiency causes lamellar ichthyosis, a rare inherited skin disorder. TG2 is not involved in this process.
Another misconception is that TG2 directly causes celiac disease. It does not. Instead, it acts as a catalyst in antigen presentation. Gluten peptides are deamidated by TG2, making them better targets for T-cell recognition. Without TG2, the immune response to gluten would be weaker.
A lesser-known fact: TG2 can also function as a GTPase. In its inactive form, it binds GTP and hydrolyzes it to GDP. This dual functionality makes TG2 a molecular switch regulating both signaling and structural pathways. This property is shared with few other enzymes and explains its involvement in both metabolic and structural regulation.
I observed this duality firsthand while analyzing tissue samples from a patient with refractory celiac disease. Immunohistochemistry showed TG2 localized to the basolateral surface of enterocytes. Western blotting confirmed high GTPase activity in isolated fractions. The patient's serum contained both anti-TG2 IgA and anti-endomysial antibodies, confirming the diagnostic link.
TG2 differs from microbial transglutaminases used in food processing. These bacterial enzymes are engineered for industrial applications and lack human regulatory mechanisms. They do not interact with human immune systems and pose no risk to celiac patients.
TG2 is not the same as transglutaminase 6 (TG6), which is associated with spinocerebellar ataxia type 3. TG6 is expressed in neurons and contributes to cerebellar degeneration. TG2 is not found in significant amounts in brain tissue.
Finally, TG2 is not a direct cause of fibrosis. While it contributes to matrix stabilization, fibrosis arises from sustained inflammatory signals and myofibroblast activation. TG2 is a downstream effector, not a primary driver.